|
Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer. |
| |
|
Honoraria - AstraZeneca; Lilly |
Consulting or Advisory Role - Alligator Bioscience; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Roche; Tusk Therapeutics |
Research Funding - Bristol-Myers Squibb; Pfizer; Tusk Therapeutics |
Travel, Accommodations, Expenses - Roche |
| |
|
Consulting or Advisory Role - Aduro Biotech; Genocea Biosciences; Incyte; MedImmune |
Research Funding - Aduro Biotech; Amgen; Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Aduro Biotech |
| |
|
Consulting or Advisory Role - Incyte; Merck |
Research Funding - Checkmate Pharmaceuticals; Incyte; Merck |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene |
Research Funding - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
Other Relationship - Celgene (I) |
| |
|
No Relationships to Disclose |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
| |
|
Employment - Bristol-Myers Squibb |
| |
|
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc. |
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc. |
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst) |
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst) |